Search results
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
Zacks via Yahoo Finance· 11 months agoImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The...
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the...
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
Zacks via Yahoo Finance· 4 months agoImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The...
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks via Yahoo Finance· 11 months agoImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings...
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat...
Institutional investors in ImmunoGen, Inc. (NASDAQ:IMGN) lost 9.0% last week but have reaped the...
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Given the large stake in the stock by institutions, ImmunoGen's stock price might be...
Wall Street Analysts See a 101.92% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?
Zacks via Yahoo Finance· 1 year agoThe mean of analysts' price targets for ImmunoGen (IMGN) points to a 101.9% upside in the stock....
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for...
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
Zacks via Yahoo Finance· 6 months agoImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is...
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
Zacks via Yahoo Finance· 8 months agoImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong...